Wall Street Zen upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST – Free Report) from a strong sell rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.
Several other research firms also recently commented on MIST. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. Cantor Fitzgerald began coverage on Milestone Pharmaceuticals in a report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.
Check Out Our Latest Analysis on MIST
Milestone Pharmaceuticals Trading Down 29.8%
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. The firm had revenue of $2.96 million for the quarter, compared to analyst estimates of $1.00 million. On average, equities analysts anticipate that Milestone Pharmaceuticals will post -0.84 earnings per share for the current year.
Institutional Trading of Milestone Pharmaceuticals
Institutional investors have recently modified their holdings of the business. RVW Wealth LLC acquired a new position in Milestone Pharmaceuticals in the third quarter valued at approximately $994,000. Seven Fleet Capital Management LP bought a new position in shares of Milestone Pharmaceuticals during the 1st quarter worth approximately $397,000. TRU Independence Asset Management 2 LLC bought a new position in shares of Milestone Pharmaceuticals during the 2nd quarter worth approximately $201,000. Renaissance Technologies LLC bought a new position in shares of Milestone Pharmaceuticals during the 1st quarter worth approximately $154,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter worth approximately $134,000. Institutional investors own 86.18% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
See Also
- Five stocks we like better than Milestone Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
